CCT251921 is a novel, potent, selective, and orally bioavailable small-molecule inhibitor of CDK8 and CDK19 (IC50 =2.3 nM; CDK19 = 2.6 nM). CCT251921 showed the optimal compromise of in vitro bioactive compound, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer. The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene.

纯度：≥98%

CAS：1607837-31-9